Inactive Instrument

Highlights Mindset Pharma Inc.

Equities

MSET

CA60268M1023

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Otsuka America, Inc. completed the acquisition of Mindset Pharma Inc..	26/10/23	CI
Mindset Pharma Agrees to be Bought by Otsuka Pharmaceutical	31/08/23	MT
Otsuka America, Inc. entered into a definitive agreement to acquire Mindset Pharma Inc. for CAD 75.9 million.	30/08/23	CI
Mindset Pharma Inc. Receives Approval for Phase II Clinical Trial Evaluating MSP-1014 for the Treatment of Major Depressive Disorder	22/06/23	CI
Mindset Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	30/05/23	CI
Mindset Pharma Inc. Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds	26/04/23	CI
Mindset Pharma CEO, James Lanthier, Issues Letter Discussing Expansion into Non-Hallucinogenic Therapeutics	28/03/23	MT
Reunion Neuroscience Filed Lawsuit Against Mindset Pharma	14/03/23	MT
Mindset Pharma Inc. and PharmAla Biotech Holdings Inc. Complete First Sale of Pharmaceutical Grade Psilocybin into Growing Australian Market Via Sales Partnership	06/03/23	CI
Mindset Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23/02/23	CI
Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs	02/02/23	CI
Mindset Pharma Receives USPTO Allowance For Application Expanding Composition of Matter for Family 1 Psilocybin Analogs	02/02/23	MT
Mindset Pharma Inc. Receives Allowance for U.S. Patent Application Covering Composition of Matter for Its Lead Psychedelic Therapeutic Candidate	20/01/23	CI
Mindset Pharma Receives US Patent Application Allowance For Lead Candidate MSP-1014, Tryptamine Prodrug Candidates	20/01/23	MT
Mindset Pharma Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	29/11/22	CI
Mindset Pharma and PharmAla Enter into Exclusive Sales Agreement for Sale and Distribution of Pharmaceutical Grade Psilocybin	16/11/22	MT
Mindset Pharma Inc. and Pharmala Biotech Holdings Inc. Enter into Exclusive Sales Agreement for the Sale and Distribution of Pharmaceutical Grade Psilocybin	16/11/22	CI
Mindset Pharma Presents Poster At Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, Its Psilocybin-Like Lead Drug Candidate	14/11/22	CI
Mindset Pharma Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	26/10/22	CI
Mindset Pharma Inc. Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio	05/10/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Mindset Pharma Inc.

Equities

MSET

CA60268M1023

Highlights

Filters